Global Hemp CBD Market Report 2022: Rise in the Demand for Hemp CBD from Various Industries Such As Food & Beverage, Personal Care and Cosmetics Drives Growth – ResearchAndMarkets.com

By -
DUBLIN--(BUSINESS WIRE)--The "Global Hemp CBD Market (2022-2027) by Distribution Channel, End-Users, and Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering. The Global Hemp CBD Market is estimated to be USD 3.3 Bn in 2022 and is expected to reach USD 7.6 Bn by 2027, growing at a CAGR of 18.15% Market Dynamics Drivers Rise in the Demand for Hemp CBD from Various Industries Such As Food & Beverage, Personal Care and Cosmetics Increasing Use of CBD-Derived Products in Pharmaceutical and Wellness Products Changing Consumer Opinion and Increasing Awareness about the Health Benefits of Cannabidiol Restraints Lack of Proper Planting & Harvesting Equipment Increasing Legalization on CBD Products Due to Various Health Side Effects Opportunities Lack of Proper Planting & Harvesting Equipment Increasing Legalization on CBD Products Due to Various Health Side Effects Challenges Stringent Transportation Regulations and Increased Warehousing Cost Market Segmentations The Global Hemp CBD Market is segmented based on Distribution Channel, End-Users, and Geography. By Distribution Channel, the market is classified into B2B and B2C. By End-Users, the market is classified into Medical, Personal Use, Pharmaceutical, and Wellness. By Geography, the market is classified into Americas, Europe, Middle-East & Africa, and Asia-Pacific. Competitive Quadrant The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc. Ansoff Analysis The report presents a detailed Ansoff matrix analysis for the Global Hemp CBD Market. Ansoff Matrix, also known as the Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The matrix can be used to evaluate approaches in four strategies viz. Market Development, Market Penetration, Product Development and Diversification. The matrix is also used for risk analysis to understand the risk involved with each approach. The analyst analyses the Global Hemp CBD Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position. Based on the SWOT analysis conducted on the industry and industry players, the analyst has devised suitable strategies for market growth. Key Topics Covered: 1 Report Description 2 Research Methodology 3 Executive Summary 4 Market Dynamics 5 Market Analysis 6 Global Hemp CBD Market, By Distribution Channel 7 Global Hemp CBD Market, By End-Users 8 Americas' Hemp CBD Market 9 Europe's Hemp CBD Market 10 Middle East and Africa's Hemp CBD Market
http://dlvr.it/Scq37V

Comments

Post a Comment

Popular posts from this blog

Hempy 2014!

By -
Image
I started 2013 with a basement full of weed and an empty bank account. I don’t know of any Seattle growers that actually got rich from growing pot this year. I think a lot of us unemployed corporate types who were laid off saw the opportunity to work for ourselves until the state could figure out what to do with the future of medical and voter approved recreational pot. A year later, the future of  medical marijuana in Washington State is still tenuous.  I have personally witnessed healing in people who use cannabis as medicine and I think it’s a crime that providers have been thrown in jail for helping others. Cannabis IS medicine and we have a God-given right to have access to it. Dispensary “donations” were my main source of income in 2013. I make half of what I used to back in my VC-funded days, but I don’t care. Money is not it. Helping people, and loving what you do on a daily basis where it’s at, man. The meaning of life is to be of service to others. Working
Read more

Coming Out of the Pot Closet

By -
Image
I have to vacuum before my mother arrives from Arizona. I’m 40-something years old and I still want her housekeeping approval. While we’re close, and speak on the phone every week, we haven’t seen each other 1:1 for a while. I’m freaking out because I think she’ll have an aneurysm when I tell her how I’ve been paying my bills the past three years. Garden of Eve The time has arrived for me to come out of the Pot Closet to my mother. How did I get here? I was laid off from my event-planning job while dating a “normal-looking” guy, who owned his own landscaping business. “Larry” also happen to own a basement full of marijuana plants for extra spending money (on prostitutes, as it turns out, but that’s a different blog post). He taught me everything I know about being a Pharmer -- from cloning and transplanting, to providing my babies with the proper nutrients and watering techniques.  I learned a lot – about the miraculous cannabis plant, and about the lying, cheating asshol
Read more

PureTech Provides End of Year Report on Key Progress

By -
Image
BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, today reported on the key progress made across its Wholly Owned Programs1 and Founded Entities2 in 2022. Daphne Zohar, Founder and Chief Executive Officer of PureTech, commented: “2022 has been a particularly successful and productive year in both crystallizing value and shaping the future of PureTech. Our primary focus is to progress our Wholly Owned Pipeline to commercialization and deliver new classes of medicines for patients with serious, debilitating conditions. We are advancing toward this goal by deepening our commitment to programs with compelling clinical data that are moving into late-stage studies and that we believe have the potential for broad impact. “Over the next 12 months, we anticipate multiple important catalysts that will further guide how we prioritize o
Read more